Jim Wang

Jim Wang

Company: Adverum Biotechnologies

Job title: Chief Regulatory Officer


Jim Wang, Ph.D., MBA, is the chief regulatory officer at Adverum Biotechnologies with 18 years of experience managing full-spectrum global drug development, marketing applications, and regulatory approvals for biologics, gene therapy, and device drug combination products. He led the global regulatory submission and approval for Luxturna, first gene therapy approved by FDA for treating a genetic disease, and Upstaza, the first marketed gene therapy product directly infused into the brain.

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.